Impact of CCR5,Integrase and Protease Inhibitors on Human Endothelial Cell Function,Stress,Inflammation and Senescence

Boccara F. , Lang S. , Meuleman C. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol 2013; 61: 511–523.

Nou E. , Lo J. , Hadigan C. , Grinspoon S.K. Pathophysiology and management of cardiovascular disease in patients with HIV. Lancet Diabetes Endocrinol 2016; 4: 598–610.

Guaraldi G. , Zona S. , Orlando G. Human immunodeficiency virus infection is associated with accelerated atherosclerosis. J Antimicrob Chemother 2011; 66: 1857–1860.

Schouten J. , Wit F.W. , Stolte I.G. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 2014; 59: 1787–1797.

DAD Study Group, Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723–1735.

Lang S. , Mary-Krause M. , Cotte L. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170: 1228–1238.

Stein J.H. , Ribaudo H.J. , Hodis H.N. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS 2015; 29: 1775–1783.

Gupta S.K. , Mi D. , Moe S.M. , Dube M.P. , Liu Z. Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial. J Acquir Immune Defic Syndr 2013; 64: 279–283.

Hatano H. , Scherzer R. , Wu Y. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection. J Acquir Immune Defic Syndr 2012; 61: 317–325.

Lake J.C. , Koteff J. , Brennan C. Cardiovascular biomarkers after switching to ABC/DTG/3TC: The STRIIVING Study. 23rd Conference on Retroviruses and Opportunistic Infections. 22–25 February 2016, Boston, MA, USA. Abstract 660.

Rojas J. , Blanco J.L. , Marcos M.A. Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression. J Antimicrob Chemother 2016; 71: 1975–1981.

Hileman C.O. , Kinley B. , Scharen-Guivel V. Differential reduction in monocyte activation and vascular inflammation with integrase inhibitor-based initial antiretroviral therapy among HIV-infected individuals. J Infect Dis 2015; 212: 345–354.

Maguire J.J. , Jones K.L. , Kuc R.E. , Clarke M.C. , Bennett M.R. , Davenport A.P. The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro. Cardiovasc Res 2014; 101: 513–521.

Cipriani S. , Francisci D. , Mencarelli A. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation 2013; 127: 2114–2124.

Piconi S. , Pocaterra D. , Rainone V. Maraviroc reduces arterial stiffness in PI-treated HIV-infected patients. Sci Rep 2016; 6: 28853.

Donato A.J. , Morgan R.G. , Walker A.E. , Lesniewski L.A. Cellular and molecular biology of aging endothelial cells. J Mol Cell Cardiol 2015; 89: 122–135.

Donato A.J. , Pierce G.L. , Lesniewski L.A. , Seals D.R. Role of NFkappaB in age-related vascular endothelial dysfunction in humans. Aging (Albany NY) 2009; 1: 678–680.

Donato A.J. , Black A.D. , Jablonski K.L. , Gano L.B. , Seals D.R. Aging is associated with greater nuclear NF kappa B, reduced I kappa B alpha, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell 2008; 7: 805–812.

Krikke M. , Tesselaar K. , Arends J.E. Maraviroc intensification improves endothelial function in abacavir-treated patients, an open-label randomized cross-over pilot study. Infect Dis Ther 2016; 5: 389–404.

van Deursen J.M. The role of senescent cells in ageing. Nature 2014; 509: 439–446.

Lagathu C.C. , Cossarizza A. , Bereziat V. , Nasi M. , Capeau J. , Pinti M. Basic science and pathogenesis of ageing with HIV: potential mechanisms and biomarkers. AIDS 2017; 31 Suppl 2: S105–S119.

Yin H. , Pickering J.G. Cellular senescence and vascular disease: novel routes to better understanding and therapy. Can J Cardiol 2016; 32: 612–623.

Auclair M. , Afonso P. , Capel E. , Caron-Debarle M. , Capeau J. Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin. Antivir Ther 2014; 19: 773–782.

Lefevre C. , Auclair M. , Boccara F. Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin. Arterioscler Thromb Vasc Biol 2010; 30: 2611–2620.

Gareus R. , Kotsaki E. , Xanthoulea S. Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell Metab 2008; 8: 372–383.

Coffinier C. , Hudon S.E. , Farber E.A. HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc Natl Acad Sci U S A 2007; 104: 13432–13437.

Coffinier C. , Hudon S.E. , Lee R. A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. J Biol Chem 2008; 283: 9797–9804.

Monforte A. , Reiss P. , Ryom L. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS 2013; 27: 407–415.

Dekker D. , Dorresteijn M.J. , Pijnenburg M. The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2011; 31: 458–463.

Liu X.M. , Durante Z.E. , Peyton K.J. , Durante W. Heme oxygenase-1-derived bilirubin counteracts HIV protease inhibitor-mediated endothelial cell dysfunction. Free Radic Biol Med 2016; 94: 218–229.

Torriani F.J. , Komarow L. , Parker R.A. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52: 569–576.

Bernal E. , Verdu J.M. , Vera F. Improvement of endothelial function after switching previously treated HIV-infected patients to an NRTI-sparing bitherapy with maraviroc. J Int AIDS Soc 2014; 17: 19726.

Diaz-Delfin J. , Domingo P. , Giralt M. , Villarroya F. Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation. Cytokine 2013; 61: 808–815.

Zhang X. , Cao R. , Liu R. Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages. PLoS One 2014; 9: e90856.

Martinez E. , D'Albuquerque P.M. , Llibre J.M. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012; 26: 2315–2326.

Silva E.F. , Charreau I. , Gourmel B. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy. J Infect Dis 2013; 208: 892–897.

Bernardino J.I. , Mocroft A. , Mallon P.W. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV 2015; 2: e464–e473.

Donato A.J. , Magerko K.A. , Lawson B.R. , Durrant J.R. , Lesniewski L.A. , Seals D.R. SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans. J Physiol 2011; 589: 4545–4554.

Winnik S. , Auwerx J. , Sinclair D.A. , Matter C.M. Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J 2015; 36: 3404–3412.

Gorenne I. , Kumar S. , Gray K. Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis. Circulation 2013; 127: 386–396.

Bonello-Palot N. , Simoncini S. , Robert S. Prelamin A accumulation in endothelial cells induces premature senescence and functional impairment. Atherosclerosis 2014; 237: 45–52.

Bidault G. , Garcia M. , Vantyghem M.C. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction. Arterioscler Thromb Vasc Biol 2013; 33: 2162–2171.

Afonso P. , Auclair M. , Boccara F. LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: role of ZMPSTE24 downregulation. Atherosclerosis 2016; 245: 200–211.

Ragnauth C.D. , Warren D.T. , Liu Y. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010; 121: 2200–2210.

Bastard J.P. , Fellahi S. , Couffignal C. Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity. J Antimicrob Chemother 2015; 70: 1816–1824.

Neuhaus J. , Jacobs D.R. Jr. , Baker J.V. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201: 1788–1795.